Seroprevalence of hepatitis A virus antibodies (anti-HAV) in adult inhabitants of Wielkopolska region, Poland – the role of simple demographic factors
More details
Hide details
Department of Infectious Diseases, University of Medical Sciences, Poznan, Poland
Department of Infectious Diseases, Jozef Strus Multidisciplinary Municipal Hospital, Poznan, Poland
Department of Computer Science and Statistics, University of Medical Sciences, Poznan, Poland
Ann Agric Environ Med 2012;19(4):738–741
Introduction and objective:
Based on the available epidemiologic data, Poland currently has the features typical for areas of very low endemicity for hepatitis A. The incidence of hepatitis A in the Wielkopolska region in years 2006-2008 was 0.68/100,000 inhabitants or significantly lower. The aim of this cross-sectional analysis was to evaluate the seroprevalence of anti-HAV antibodies in inhabitants of the Wielkopolska region of western Poland regarding some demographic factors.

Material and Methods:
In addition to testing anti-HAV antibodies, the medical history and demographic data, such as age, gender, place of residence, and level of education of 680 patients and 105 healthy blood donors were analyzed.

Anti-HAV antibodies were observed in 235 cases (29.9%). In univariate regression analysis, the covariates correlated with positive anti-HAV testing were age, female gender and lower level of education. Only 6.2% of young adults were seropositive. Among study participants above the age of 50, anti-HAV antibodies were present in 64-100% of cases. An icteric disease consistent with hepatitis A diagnosis was identified in the histories of 10.2% of seropositive patients.

The risk for contracting disease after exposure to HAV in young (<40 years old) inhabitants of the Wielkopolska region is high. Apart from older individuals, also women and people with a lower level of education are more frequently seropositive. A low level of immunity to HAV should be an indication for vaccination against HAV , especially in selected groups.

1. Pringle CR. Virus taxonomy at the XI th International Congress of Virology, Sydney, Australia, 1999. Arch Virol. 1999; 144(10): 2065-2070.
2. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001; 14(1): 38-58.
3. Koff RS. Hepatitis A. Lancet 1998; 351(9116): 1643-1649.
4. Baumann A. Wirusowe zapalenie wątroby typu A w Polsce w latach 2006-2007 (Hepatitis A in Poland in the years 2006-2007). Przegl Epidemiol. 2009; 63(2): 241-244 (in Polish).
5. Baumann A. Wirusowe zapalenie wątroby typu A w Polsce w 2008 roku (Hepatitis A in Poland in 2008). Przegl Epidemiol. 2010; 64(2): 235-237 (in Polish).
6. Janaszek-Seydlitz W, Bucholc B, Wiatrzyk A. Poziom przeciwciał przeciwko wirusowemu zapaleniu wątroby typu A u osób z terenu Warszawy (Prevalence of anti-HAV antibodies in Warsaw population). Przegl Epidemiol. 2007; 61(4): 675-682 (in Polish).
7. Cianciara J. Hepatits A shifting in Poland and Eastern Europe. Vaccine 2000; 18 (Suppl. 1): S68-S70.
8. Meldunki o zachorowaniach na choroby zakaźne, zakażeniach i zatruciach w Polsce (Reports on morbidity of infectious diseases and poisonings in Poland) (in Polish). (access: 2011.03.03).
9. Magdzik W, Czarkowski MP. Zmiany w endemiczności wirusowego zapalenia wątroby typu A (wzw A) w Polsce (Changes in endemicity at hepatitis A in Poland). Przegl Epidemiol. 2004; 58(1): 3-8 (in Polish).
10. Cianciara J, Gładysz A, Juszczyk J, Drozdowicz A, Duszczyk E, Łoch T, et al. Próba oceny sytuacji epidemicznej zakażeń HAV w Polsce – wyniki badań przesiewowych anty-HAV klasy IgG (Epidemiology of hepatitis A in Poland – serological surveys). In: Juszczyk J (Ed): Hepatitis A Compendium, SmithKline Beecham Pharmacuticals, Warszawa 1997. p. 29-35 (in Polish).
11. Polz-Dacewicz MA, Policzkiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection – a comparative study in Central Eastern Poland (1990-1999). Med Sci Monit. 2000; 6(5): 989-993.
12. Chlabicz S, Grzeszczuk A. Przewlekłe zapalenie wątroby typu C a ryzyko zakażenia wirusem zapalenia wątroby typu A (Chronic hepatitis C and risk for hepatitis A infection). Przegl Epidemiol. 2001; 55(3): 281-286 (in Polish).
13. Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic? J Viral Hepat. 2000; 7 (Suppl. 1): 1-3.
14. Frank C, Walter J, Muehlen M, Jansen A, van Treeck U, Hauri AM, et al. Major outbreak of hepatitis A associated with orange juice among tourists, Egypt, 2004. Emerg Infect Dis. 2007; 13(1): 156-158.
15. Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT, et al. A multistate, foodborne outbreak of hepatitis A. N Engl J Med. 1999; 340(8): 595-602.
16. Państwowa Inspekcja Sanitarna – Powiatowa Stacja Sanitarno-Epidemiologiczna w Gostyniu. Ocena stanu sanitarnego i sytuacja epidemiologiczna powiatu gostyńskiego w roku 2009 (State Sanitary Inspection – Gostyn Sanitary Inspectotate: Sanitary condition and epidemiological situation in Gostyn district in 2009) (in Polish). (access: 2011.03.03).
17. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294(2): 202-210.
18. Vacchino MN. Incidence of Hepatitis A in Argentina a er vaccination. Viral Hepat. 2008; 15 (Suppl. 2): 47-50.
19. Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362(9389): 1065-1071.
20. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007; 5(2): 79-84.
21. Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007; 357(17): 1685-1694.
22. Havrix Adult – Charakterystyka Produktu Leczniczego (Havrix Adult – full prescribing information) (in Polish). (access: 2011.03.03).
23. Komunikat Głównego Inspektora Sanitarnego z dnia 28 października 2010r. w sprawie Programu Szczepień Ochronnych na rok 2011 (załącznik) (Chief Sanitary Inspector announcement about National Vaccination Program 2011 [appendix]) (in Polish). les/ le/Departament%20Przeciwepidemiczny/szczepienia/PSO%20na%202011.pdf (access: 2011.03.03).
24. Cotter SM, Sansom S, Long T, Koch E, Kellerman S, Smith F, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis. 2003; 187(8): 1235-1240.
25. Mazick A, Howitz M, Rex S, Jensen IP, Weis N, Katzenstein TL, et al. Hepatitis A outbreak among MSM linked to casual sex and gay saunas in Copenhagen, Denmark. Euro Surveill. 2005; 10(5): 111-114.
26. Staes CJ, Schlenker TL, Risk I, Cannon KG, Harris H, Pavia AT, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 2000; 106(4): e54.
27. Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for Vaccination. Vaccine 2003; 21(19-20): 2238-2241.
28. Kee e EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995; 90(2): 201-205.
29. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998; 338(5): 286-290.